PLYMOUTH, Minn., April 20 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq:
EVVV), a global medical device company focused on catheter-based
technologies for the endovascular treatment of vascular diseases and
disorders, announced today that it has priced its previously announced
secondary offering at $19.00 per share. A total of 6,250,000 common shares
are being sold by Warburg Pincus and The Vertical Group with an additional
2,500,000 common shares being offered by the company. Warburg Pincus has
granted the underwriters an option to purchase up to an additional
1,312,500 shares of common stock to cover over-allotments, if any.
(Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGO)
The joint book-running managers for the offering are Banc of America
Securities LLC, Piper Jaffray & Co. and J.P. Morgan Securities Inc., with
Bear, Stearns & Co. Inc. and Thomas Weisel Partners LLC acting as co-
managers.
A copy of the prospectus related to the offering may be obtained by
contacting either: Banc of America Securities LLC, Capital Markets
(Prospectus Fulfillment) by e-mail to
dg.prospectus_distribution@bofasecurities.com or by mail to Banc of America
Securities LLC, Capital Markets Operations, 100 West 33rd Street, 3rd
Floor, New York, NY 10001; Piper Jaffray & Co., 800 Nicollet Mall, Suite
800, Minneapolis, MN 55402; or J.P. Morgan Securities Inc., Prospectus
Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission and was declared effective on
April 19, 2007. This news release does not constitute an offer to sell or
the solicitation of an offer to buy the securities, nor shall there be any
sale of securities in any state in which such offer, solicitation or sale
would be unlawful prior to registration or qualification of the securities
under the securities laws of that state.
About ev3 Inc.
ev3 is a global medical device company focused on catheter-based
technologies for the endovascular treatment of vascular diseases and
disorders. For more information, please visit http://www.ev3.net.
Statements contained in this press release that are not historical
information are forward-looking statements as defined within the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
are subject to risks and uncertainties that could cause actual results to
differ materially from those projected or implied. Such potential risks and
uncertainties relate, but are not limited to, in no particular order:
product demand and market acceptance, the impact of competitive products
and pricing, and success of clinical testing. More detailed information on
these and additional factors which could affect ev3 Inc.'s operating and
financial results are described in the company's filings with the
Securities and Exchange Commission, including its most recent annual report
on Form 10-K. ev3 Inc. urges all interested parties to read this report to
gain a better understanding of the many business and other risks that the
company faces. Additionally, ev3 Inc. undertakes no obligation to publicly
release the results of any revision to these forward-looking statements,
which may be made to reflect events or circumstances occurring after the
date hereof or to reflect the occurrence of unanticipated events.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S.
and other countries.
SOURCE ev3 Inc.
 back to top
Related links:
http://www.ev3.net
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Patrick Spangler, CFO of ev3 Inc.,
+1-763-398-7000, pspangler@ev3.net; or Media, Laura Nobles of
Nobles Communications, +1-310-795-0497,
laura@noblescommunications.com, for ev3 Inc.; or Investor, Marian
Briggs of Padilla Speer Beardsley, +1-612-455-1742,
mbriggs@psbpr.com, for ev3 Inc.
|
